News

MRNA Q2 Deep Dive: Revenue Beat Overshadowed by Lower Guidance and Cost Cuts

Biotechnology company Moderna (NASDAQ:MRNA) announced better-than-expected revenue in Q2 CY2025, but sales fell by 41.1% year ...

Robert F. Kennedy Jr.’s Impact So Far: ‘The Worst Possible Case’

David Wallace-Wells and Emily Oster argue that the effects of MAHA will be long-lasting.